Fate Therapeutics Inc (NASDAQ:FATE) currently has a daily average trading volume of 1.65M but it saw 2373038 shares traded in last market. With a market cap of 252.85M USD, the company’s current market price of $2.22 came rising about 1.83 while comparing to the previous closing price of $2.18. In past 52 weeks, the stock remained buoying in the range of price level as high as $8.83 and as low as $1.96. In the recent trading on the day, stock has struck highest price mark of $2.03 while lowest mark touched by it was $2.35.
Taking a look at 20-day trading activity of Fate Therapeutics Inc (FATE) gives us an average price of $2.47, while its current price level is -74.86% below from 52-week high level whereas it is 13.27% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $3.02 while that of 200 days or SMA-200 reads an average of $4.42. A closer look into the stock’s movement over the week reveals that its volatility is standing at 20.05% during that period while stretching the period over a month that decreases to 12.52%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 39.19 which implies that the stock is in neutral territory.
Piper Sandler upgraded its recommendation for the stock as a “Overweight” from “Neutral” on June 17, 2024 while assigning a price target range of $4-$6. Wells Fargo issued its recommendations for the stock as it resumed the price target for the stock is $6.
Over the week, FATE’s stock price is moving 2.30% up while it is -30.41% when we observe its performance for the past one month. Year-to-date it is -40.64% down and over the past year, the stock is showing a downside performance of -14.62%.
Currently, Fate Therapeutics Inc’s total number of outstanding shares is 98.63M. Company’s return on investment (ROI) stands at -39.22% and return on equity (ROE) at -46.59%. Stock’s beta reads 1.86. Stock has a price to book (P/B) ratio of 0.70 while price to sale or P/S ratio amounts to 18.80. Its return on asset (ROA) is -34.32% on average.
